RxDoctor Payments DataLook up a doctor →

James Adamo, MD

Psychiatry · Roseville, MINPI 1851311021

Payments from drug & device makers

$27,704in general payments, 2019–2025

Across 1,631 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$3K
  • Otsuka America Pharmaceutical, Inc.$3K
  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Neurocrine Biosciences, Inc.$2K
  • Johnson & Johnson$2K
  • plus $14K from 36 others

What the payments were for

  • Speaking & faculty fees$9904%
  • Food & beverage$26,59796%
  • Education$1170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,704 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.

See all psychiatry providers in Michigan

Medicare billing

Part B allowed, 2024
$283,941
Medicare patients
298
Services billed
2,456

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate18$56,479
VraylarCariprazine Hcl34$50,984
FanaptIloperidone13$26,437
TrintellixVortioxetine Hydrobromide29$23,526
OzempicSemaglutide13$14,895
FetzimaLevomilnacipran Hcl15$11,350
Lurasidone Hcl17$9,412
Dyanavel XrAmphetamine11$4,818
Vilazodone Hcl38$4,128
Aripiprazole79$3,202
Venlafaxine Hcl ErVenlafaxine Hcl57$2,667
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine63$2,501
Duloxetine Hcl129$2,456
Clozapine37$2,398
Methylphenidate ErMethylphenidate Hcl24$2,078

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$2,432$62,33549 claims
Johnson & JohnsonInvega Sustenna$1,802$56,47918 claims
Vanda Pharmaceuticals Inc.Fanapt$1,099$26,43713 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$790$23,52629 claims
Novo NordiskOzempic$75$14,89513 claims
Tris Pharma IncDyanavel Xr$882$4,81811 claims
Lilly USA, LLCOlanzapine$37$2,00833 claims
Almatica Pharma LLCSertraline Hcl$409$78861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.

Other psychiatry in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →